This study aimed to identify and compare risk factors associated with canine leptospirosis and Leptospira seropositivity in New South Wales, Australia. Seventy-nine canine cases of confirmed leptospirosis (clinical cases) and 16 healthy dogs seropositive to Leptospira (seropositive cases) were included in the study; these were separately compared to 394 healthy dogs seronegative to Leptospira (controls) in at-risk areas. A questionnaire investigated rat contact, stagnant water, dog park access and household number of dogs and cats.
View Article and Find Full Text PDFHighly fatal canine leptospirosis emerged in urban Sydney dogs in 2017, and serovar Copenhageni, against which a registered monovalent vaccine is available, was predominant until 2020. This study was conducted to (1) determine serological characteristics of canine leptospirosis in New South Wales (NSW) between 2021 and 2023; (2) describe the geospatial distribution of leptospirosis; and (3) evaluate if clinicopathological abnormalities and outcome differ between the dominant infecting serovars, Copenhageni versus Australis. Cases were identified through referral or direct veterinarian contact and included if clinical and clinicopathological findings confirmed leptospirosis.
View Article and Find Full Text PDFIn 2017, highly fatal canine leptospirosis emerged in Sydney, Australia. Based on results of microscopic agglutination testing (MAT), serovar Copenhageni appeared to be the most common causative serovar. Prior to this, no clinical cases had been reported since 1976.
View Article and Find Full Text PDF